Clinical-stagestemcellgroupReNeuronhasachievedfurthersignificantmilestoneswithitsReN001andReN009programmesinstrokeandcriticallimbischaemia,withthefilingoftwofurtherclinicaltrialapplicationstoprogresstheclinicaldevelopmentofthesenoveltherapies。

MichaelHunt,ChiefExecutiveOfficerofReNeuron,toldshareholdersatthecompanysannualgeneralmeetingthatthefirmremainsfundedforthenext12months,butwillpursuearangeoffundingoptionsincludingnon-dilutivegrants。

ShopfitterHavelockEuropesawgrouprevenuefromcontinuingoperationsriseby17%to£38。

5minthefirsthalfof2012from£32。

9mtheyearbefore。

Theunderlyingpre-taxlossnarrowedto£1。

2mfromalossof£2。

8mthepreviousyear。

Thegoodnewsisthatthecompanymadeaprofitaftertaxof£7。

3m,versusalossof£1。

1minthefirsthalfof2011,aftertrouseringanexceptionalgainof£8。

0mfromthesaleofitsprintdivision。

Groupnetdebteasedto£2。

3mfrom£13。

7m。

Lookingahead,themarketswillcontinuetoremainchallenging。